Thomas W. Battaglia
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.
Journal: Cell reports. Medicine
Published: April 14, 2025
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.
Journal: Cancer discovery
Published: November 14, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Journal: The Journal of pathology
Published: October 09, 2023
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.
Journal: The Journal of clinical investigation
Published: April 03, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Journal: BMC cancer
Published: December 20, 2022
A pan-cancer analysis of the microbiome in metastatic cancer.
Journal: Cell
Published: October 11, 2022
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
Journal: Nature
Published: July 16, 2021
Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.
Journal: Nature biotechnology
Published: February 24, 2021
Fecal Microbiome Characteristics and the Resistome Associated With Acquisition of Multidrug-Resistant Organisms Among Elderly Subjects.
Journal: Frontiers in microbiology
Published: June 27, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026